Key clinical point: Pazopanib appears efficacious and safe for treating neoplasms associated with von Hippel-Lindau disease.
Major finding: The objective response rate was 42% overall, with response seen in 52% of renal cell carcinomas.
Study details: Single-center, single-arm, open-label, phase 2 trial among 31 adult patients with clinical manifestations of von Hippel-Lindau disease who were treated with pazopanib for at least 24 weeks.
Disclosures: Dr. Jonasch disclosed that he receives research support and honoraria from Novartis. The study was funded by Novartis and by a National Institutes of Health National Cancer Institute core grant.
Jonasch E et al. Lancet Oncol. 2018 Sep 17. doi: 10.1016/S1470-2045(18)30487-X
This Week's Must Reads
Must Reads in Renal Cell Carcinoma
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.
Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001
One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617